Cardiac involvement is a defining feature of Hantavirus Cardiopulmonary Syndrome (HCPS) and a significant complication in Hemorrhagic Fever with Renal Syndrome (HFRS). While historical views categorized the cardiac dysfunction as purely functional, modern evidence confirms a combination of direct viral effects and a profound cytokine-mediated inflammatory response that leads to myocardial depression and shock.
1. Pathophysiology and Mechanisms
The hallmark of cardiac involvement in hantavirus infection is increased microvascular permeability and myocardial depression without significant direct cytopathic damage to myocytes.
- “Typical” Myocarditis: Foundational studies identified hantaviral antigens and particles specifically within the cardiac endothelium and interstitial macrophages, accompanied by interstitial edema and myofiber necrosis.
- The Cytokine Storm: Myocardial depression is largely attributed to high levels of soluble mediators, including TNF-α, IFN-γ, and nitric oxide (NO). These cytokines impair endothelial function and directly inhibit myocardial contractility.
- Functional vs. Structural: The shock state is an “atypical septic shock” where low cardiac index (CI) and low stroke volume index (SVI) are accompanied by high systemic vascular resistance (SVR), mimicking cardiogenic shock.
2. Clinical and Hemodynamic Profile
Electrocardiographic (ECG) and Imaging Findings
- ECG Abnormalities: Patients often present with sinus tachycardia in some variants or bradycardia in other variants. Severe cases can mimic ST-elevation myocardial infarction (STEMI) due to diffuse ST-segment changes and wall motion abnormalities on echocardiography.
- Echocardiography: Typical findings include depressed Left Ventricular Ejection Fraction (LVEF) (often 35–40%) and pericardial effusion. Remarkably, myocardial function may recover fully in survivors within 2–4 weeks.
3. Long-Term Cardiovascular Outcomes
Survivors of severe hantavirus infection may face persistent cardiovascular and systemic burden:
- Persistent Symptoms: Up to 80% of survivors report long-term fatigue, and over 50% experience persistent dyspnea 3–6 months post-discharge, regardless of whether they required ECMO (Ares-Gómez et al., 2025).
- Late Complications: Long-term follow-up of survivors of certain variants has indicated an increased risk for acute myocardial infarction, hypertension, and venous thromboembolism (PMC8953343, 2022).
References
Ares-Gómez, S., et al. (2025). Beyond ECMO Survival: Long-Term Symptom Burden and Quality-of-Life Impairment in Hantavirus Cardiopulmonary Syndrome Survivors. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12474361/
Bugedo, G., et al. (2016). Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration.
ECDC. (2026). Factsheet on orthohantavirus infections. https://www.ecdc.europa.eu/en/infectious-disease-topics/hantavirus-infection/factsheet-orthohantavirus-infections
Nichol, S. T., Spiropoulou, C. F., Morzunov, S., Rollin, P. E., Ksiazek, T. G., Feldmann, H., et al. (1993). Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science, 262(5135), 914–917.
Puurunen, A. S., et al. (2013). Cardiopulmonary involvement in Puumala hantavirus infection. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4231367/
StatPearls. (2026). Hantavirus Pulmonary Syndrome. https://www.ncbi.nlm.nih.gov/books/NBK513243/
Zaki, S. R., et al. (1995). Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. American Journal of Pathology, 146(3), 552-579.